PYC 0.00% 19.0¢ pyc therapeutics limited

Ann: Successful GLP Tox Studies in Second Blinding Eye Disease, page-10

ANNOUNCEMENT SPONSORED BY PLUS500
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM
CFD Service. Your Capital is at risk
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
ANNOUNCEMENT SPONSORED BY PLUS500
CFD TRADING PLATFORM CFD Service. Your Capital is at risk
  1. 838 Posts.
    lightbulb Created with Sketch. 71
    When results start coming through, there will be a belated realization of the potential.

    There are currently around 7,000 known monogenic diseases caused by mutations in a single gene. However, a recent study identified 72 monogenic disorders that have a prevalence of at least 1 in 20,000 individuals in the human population. Of these, 34 are caused exclusively by mutations in a single gene. The number of known monogenic diseases continues to grow as gene discovery efforts advance, aided by technologies like whole exome/genome
    sequencing.
    https://pubmed.ncbi.nlm.nih.gov/34515378/

    Stoke therapeutics have identified approximately 1,200 monogenic diseases and approximately 6,500 additional genes with RNA target signatures which we believe to be amenable to TANGO.
    Last edited by Counterfiat: 14/05/24
 
watchlist Created with Sketch. Add PYC (ASX) to my watchlist
(20min delay)
Last
19.0¢
Change
0.000(0.00%)
Mkt cap ! $863.2M
Open High Low Value Volume
19.0¢ 19.0¢ 18.5¢ $165.9K 879.3K

Buyers (Bids)

No. Vol. Price($)
2 56706 18.5¢
 

Sellers (Offers)

Price($) Vol. No.
19.0¢ 201871 8
View Market Depth
Last trade - 14.14pm 04/11/2024 (20 minute delay) ?
PYC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.